CoChat
Sign Up
Cited by 47

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

The Epigenetic Drug 5-Azacytidine Interferes with Cholesterol and Lipid Metabolism

Poirier, Steve, Samami, Samaneh, Mamarbachi, Maya, Demers, Annie, Chang, Ta Yuan, Vance, Dennis E., Hatch, Grant M., Mayer, Gaétan·2014·Journal of Biological Chemistry
DOI 10.1074/jbc.m114.563650
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m114.563650

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several compounds known to increase LDLR mRNA stability directly have also been reported to decrease expression of SREBP-regulated genes, including PCSK9, exhibiting a dual effect.

    “Interestingly, while these compounds are known to increase LDLR mRNA stability directly, several have also been reported to decrease the expression of SREBP-regulated genes, including PCSK9, thus exhibiting a dual effect that could have significant implications for cholesterol management [19,35,42].”

    From The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms (2025) · cites this paper as [42]

  • Triciribine shares with berberine and 5-AzaC the traits of inhibition of DNA synthesis, induction of ERK activity, stabilization of LDLR mRNA, and inhibition of PCSK9 expression.

    “Interestingly, triciribine shares a number of similar traits with berberine and 5-AzaC: 1) inhibition of DNA synthesis, 2) induction of ERK activity, 3) stabilization of LDLR mRNA and 4) inhibition of PCSK9 expression11,34,35,49–51.”

    From Triciribine increases LDLR expression and LDL uptake through stabilization of LDLR mRNA (2018) · cites this paper as [35]

  • The effects of triciribine on LDLR mRNA stability and PCSK9 levels were reminiscent of those elicited by berberine and 5-Azacytidine (5-AzaC).

    “The effects of triciribine on LDLR mRNA stability and PCSK9 levels were reminiscent of those elicited by berberine and 5-Azacytidine (5-AzaC)11,34,35.”

    From Triciribine increases LDLR expression and LDL uptake through stabilization of LDLR mRNA (2018) · cites this paper as [35]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 53

  1. Jaenisch, 2003, Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals, Nat. Genet, 33, 245, 10.1038/ng1089 · DOI · Paper page
  2. Gnyszka, 2013, DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer, Anticancer Res, 33, 2989
  3. Estey, 2013, Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia, Leukemia, 27, 1803, 10.1038/leu.2013.173 · DOI
  4. Hollenbach, 2010, A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines, PLoS One, 5, e9001, 10.1371/journal.pone.0009001 · DOI
  5. Flotho, 2009, The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells, Leukemia, 23, 1019, 10.1038/leu.2008.397 · DOI
  6. Cihák, 1974, Biological effects of 5-azacytidine in eukaryotes, Oncology, 30, 405, 10.1159/000224981 · DOI
  7. Vigna, 2011, Epigenetic regulation in myelodysplastic syndromes: implications for therapy, Expert Opin. Investig. Drugs, 20, 465, 10.1517/13543784.2011.559164 · DOI
  8. Aimiuwu, 2012, RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia, Blood, 119, 5229, 10.1182/blood-2011-11-382226 · DOI
  9. Brown, 2009, Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL, J. Lipid Res, 50, S15, 10.1194/jlr.R800054-JLR200 · DOI · Paper page
  10. Moon, 2012, The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals, Cell Metab, 15, 240, 10.1016/j.cmet.2011.12.017 · DOI · Paper page
  11. Tang, 2011, Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques, Cell Metab, 13, 44, 10.1016/j.cmet.2010.12.004 · DOI · Paper page
  12. Global Lipids Genetics Consortium, 2013, Discovery and refinement of loci associated with lipid levels, Nat. Genet, 45, 1274, 10.1038/ng.2797 · DOI
  13. Rakyan, 2011, Epigenome-wide association studies for common human diseases, Nat. Rev. Genet, 12, 529, 10.1038/nrg3000 · DOI
  14. Ehara, 2012, Role of DNA methylation in the regulation of lipogenic glycerol-3-phosphate acyltransferase 1 gene expression in the mouse neonatal liver, Diabetes, 61, 2442, 10.2337/db11-1834 · DOI
  15. Mayer, 2008, The regulated cell surface zymogen activation of the proprotein convertase PC5A directs the processing of its secretory substrates, J. Biol. Chem, 283, 2373, 10.1074/jbc.M708763200 · DOI
  16. Horton, 1998, Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2, J. Clin. Invest, 101, 2331, 10.1172/JCI2961 · DOI
  17. Hua, 1996, Sterol resistance in CHO cells traced to point mutation in SREBP cleavage-activating protein, Cell, 87, 415, 10.1016/S0092-8674(00)81362-8 · DOI · Paper page
  18. Rawson, 1997, Complementation cloning of S2P, a gene encoding a putative metalloprotease required for intramembrane cleavage of SREBPs, Mol. Cell, 1, 47, 10.1016/S1097-2765(00)80006-4 · DOI · Paper page
  19. Chang, 1993, Molecular cloning and functional expression of human acyl-coenzyme A:cholesterol acyltransferase cDNA in mutant Chinese hamster ovary cells, J. Biol. Chem, 268, 20747, 10.1016/S0021-9258(19)36846-2 · DOI
  20. Huang da, 2009, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources, Nat. Protoc, 4, 44, 10.1038/nprot.2008.211 · DOI · Paper page
  21. Li, 2009, Hepatocyte nuclear factor 1α plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine, J. Biol. Chem, 284, 28885, 10.1074/jbc.M109.052407 · DOI
  22. Jeong, 2008, Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2, J. Lipid Res, 49, 399, 10.1194/jlr.M700443-JLR200 · DOI · Paper page
  23. Seidah, 2012, Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation, PLoS One, 7, e41865, 10.1371/journal.pone.0041865 · DOI · Paper page
  24. Wang, 1994, SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis, Cell, 77, 53, 10.1016/0092-8674(94)90234-8 · DOI
  25. Pelech, 1981, cAMP analogues inhibit phosphatidylcholine biosynthesis in cultured rat hepatocytes, J. Biol. Chem, 256, 8283, 10.1016/S0021-9258(19)68839-3 · DOI
  26. Hatch, 1996, Regulation of cardiolipin biosynthesis in H9c2 cardiac myoblasts by cytidine 5′-triphosphate, J. Biol. Chem, 271, 25810, 10.1074/jbc.271.42.25810 · DOI
  27. Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat. Genet, 34, 154, 10.1038/ng1161 · DOI · Paper page
  28. Horton, 2003, Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes, Proc. Natl. Acad. Sci. U.S.A, 100, 12027, 10.1073/pnas.1534923100 · DOI · Paper page
  29. Cameron, 2008, Berberine decreases PCSK9 expression in HepG2 cells, Atherosclerosis, 201, 266, 10.1016/j.atherosclerosis.2008.02.004 · DOI
  30. Poirier, 2013, The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol, Drug Des. Devel. Ther, 7, 1135
  31. Maxwell, 2003, Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice, J. Lipid Res, 44, 2109, 10.1194/jlr.M300203-JLR200 · DOI · Paper page
  32. Sato, 1996, Sterol-dependent transcriptional regulation of sterol regulatory element-binding protein-2, J. Biol. Chem, 271, 26461, 10.1074/jbc.271.43.26461 · DOI
  33. Cao, 2006, Molecular identification of microsomal acyl-CoA:glycerol-3-phosphate acyltransferase, a key enzyme in de novo triacylglycerol synthesis, Proc. Natl. Acad. Sci. U.S.A, 103, 19695, 10.1073/pnas.0609140103 · DOI
  34. Lagace, 2013, The role of phospholipids in the biological activity and structure of the endoplasmic reticulum, Biochim. Biophys. Acta, 1833, 2499, 10.1016/j.bbamcr.2013.05.018 · DOI
  35. Jamal, 1991, Plasma membrane fractions from rat liver contain a phosphatidate phosphohydrolase distinct from that in the endoplasmic reticulum and cytosol, J. Biol. Chem, 266, 2988, 10.1016/S0021-9258(18)49945-0 · DOI
  36. Meza-Avina, 2010, Structural determinants for the inhibitory ligands of orotidine-5′-monophosphate decarboxylase, Bioorg. Med. Chem, 18, 4032, 10.1016/j.bmc.2010.04.017 · DOI
  37. Carter, 1966, Enzymatic synthesis of cytidine diphosphate diglyceride, J. Lipid Res, 7, 678, 10.1016/S0022-2275(20)39250-6 · DOI
  38. Keating, 2012, Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia, Drugs, 72, 1111, 10.2165/11209430-000000000-00000 · DOI
  39. Abidi, 2005, Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine, Arterioscler. Thromb. Vasc. Biol, 25, 2170, 10.1161/01.ATV.0000181761.16341.2b · DOI · Paper page
  40. Lehner, 2012, Lumenal lipid metabolism: implications for lipoprotein assembly, Arterioscler. Thromb. Vasc. Biol, 32, 1087, 10.1161/ATVBAHA.111.241497 · DOI
  41. Sokolov, 2010, Accessibility of cholesterol in endoplasmic reticulum membranes and activation of SREBP-2 switch abruptly at a common cholesterol threshold, J. Biol. Chem, 285, 29480, 10.1074/jbc.M110.148254 · DOI · Paper page
  42. Raabe, 1999, Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice, J. Clin. Invest, 103, 1287, 10.1172/JCI6576 · DOI · Paper page
  43. Newberry, 2003, Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene, J. Biol. Chem, 278, 51664, 10.1074/jbc.M309377200 · DOI
  44. Sturley, 2012, Lipid droplet formation on opposing sides of the endoplasmic reticulum, J. Lipid Res, 53, 1800, 10.1194/jlr.R028290 · DOI
  45. Shan, 2010, GPAT3 and GPAT4 are regulated by insulin-stimulated phosphorylation and play distinct roles in adipogenesis, J. Lipid Res, 51, 1971, 10.1194/jlr.M006304 · DOI
  46. Schulze, 2012, How cancer metabolism is tuned for proliferation and vulnerable to disruption, Nature, 491, 364, 10.1038/nature11706 · DOI
  47. Shao, 2012, Expanding roles for SREBP in metabolism, Cell Metab, 16, 414, 10.1016/j.cmet.2012.09.002 · DOI
  48. Ellis, 2012, Alteration of lipids and the transcription of lipid-related genes in myelodysplastic syndromes via a TP53-related pathway, Exp. Hematol, 40, 540, 10.1016/j.exphem.2012.02.003 · DOI
  49. Williams, 2013, An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity, Cancer Res, 73, 2850, 10.1158/0008-5472.CAN-13-0382-T · DOI
  50. Fozza, 2009, Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4+ subset and oligoclonal in the CD8+ subset, Exp. Hematol, 37, 947, 10.1016/j.exphem.2009.04.009 · DOI
  51. Santos, 2012, Lipid metabolism in cancer, FEBS J, 279, 2610, 10.1111/j.1742-4658.2012.08644.x · DOI
  52. Abbas, 2012, Survival outcome of veterans with myelodysplastic syndrome (MDS) treated with statins, J. Clin. Oncol, 30, e17018, 10.1200/jco.2012.30.15_suppl.e17018 · DOI
  53. van Besien, 2013, Antileukemic properties of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, Leuk. Lymphoma, 54, 2601, 10.3109/10428194.2013.790022 · DOI

Cited by

Sorted by citations

Metadata

Authors
Poirier, S., Samami, S., Mamarbachi, M., Demers, A., Chang, T. Y., Vance, D. E., Hatch, G. M., & Mayer, G.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2014-07
Volume
289
Issue
27
Pages
18736-18751
ISSN
0021-9258
DOI
10.1074/jbc.m114.563650
Cited by
47
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review